Synthesis of 99m Tc-biphenyl-2-ylcarbamoylmethyliminodiacetic acid for hepatobiliary imaging

Abstract

Biphenyl-2-ylcarbamoylmethyliminodiacetic acid (BPIDA) was synthesized, characterized, and labeled with 99m Tc using stannous chloride as reducing agent. The parameters affecting the labeling yield of 99m Tc-BPIDA were studied in detail. The optimum conditions ensuring the 99m Tc-BPIDA labeling yield as high as 85.4 ± 3% are as follows: 2 mg of BPIDA, 20 μg of SnCl 2 ·2H 2 O, pH 6, 15 min. Biodistribution of 99m Tc-BPIDA revealed high liver uptake (18.63% at 10 min) which is higher than that of commercially available 99m Tc-Mebrofenin. The liver activity decreased with time, reaching 5.2% at 180 min. Most of the administrated radioactivity is accumulated in the liver, and the activity becomes visible in the gallbladder within 15 min. 99m Tc-BPIDA can be applied as a hepatobiliary imaging agent for the evaluation of the functional status of the hepatocytes and the patency of the biliary duct.